alendronate has been researched along with Scleritis in 6 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Scleritis: Refers to any inflammation of the sclera including episcleritis, a benign condition affecting only the episclera, which is generally short-lived and easily treated. Classic scleritis, on the other hand, affects deeper tissue and is characterized by higher rates of visual acuity loss and even mortality, particularly in necrotizing form. Its characteristic symptom is severe and general head pain. Scleritis has also been associated with systemic collagen disease. Etiology is unknown but is thought to involve a local immune response. Treatment is difficult and includes administration of anti-inflammatory and immunosuppressive agents such as corticosteroids. Inflammation of the sclera may also be secondary to inflammation of adjacent tissues, such as the conjunctiva.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report a case of orbital and ocular inflammation secondary to the use of intravenous zoledronic acid and a case of scleritis secondary to oral alendronate." | 4.12 | [Bisphosphonate-induced ocular and orbital inflammation]. ( Funding, M; Jakobsen, TS, 2022) |
| "The alendronate was discontinued, and, with the administration of prednisone, the symptoms of scleritis fully resolved." | 2.43 | Bisphosphonate-associated scleritis: a case report and review. ( Ashar, BH; Leung, S; Miller, RG, 2005) |
| "Uveitis and scleritis are the most serious ocular side effects of bisphosphonate therapy." | 1.35 | Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. ( French, DD; Margo, CE, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jakobsen, TS | 1 |
| Funding, M | 1 |
| Samalia, P | 1 |
| Sims, J | 1 |
| Niederer, R | 1 |
| French, DD | 1 |
| Margo, CE | 1 |
| Fraunfelder, FW | 1 |
| Winthrop, K | 1 |
| Suhler, E | 1 |
| Choi, D | 1 |
| Fraunfelder, FT | 1 |
| Leung, S | 1 |
| Ashar, BH | 1 |
| Miller, RG | 1 |
| Mbekeani, JN | 1 |
| Slamovits, TL | 1 |
| Schwartz, BH | 1 |
| Sauer, HL | 1 |
1 review available for alendronate and Scleritis
| Article | Year |
|---|---|
Bisphosphonate-associated scleritis: a case report and review.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Female; Humans; Osteoporosis, Postmenopausal; | 2005 |
5 other studies available for alendronate and Scleritis
| Article | Year |
|---|---|
[Bisphosphonate-induced ocular and orbital inflammation].
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Inflammation; Scleritis | 2022 |
Drug-induced ocular inflammation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Allopurinol; Anti-Inflammatory Agents, Non- | 2020 |
Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Databa | 2008 |
Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Databases, Factual; Diphosphona | 2009 |
Ocular inflammation associated with alendronate therapy.
Topics: Aged; Alendronate; Endophthalmitis; Female; Humans; Middle Aged; Myositis; Scleritis | 1999 |